搜尋
VolitionRX Ltd
VNRX添加自選
1.400USD
+0.020+1.47%
收盤 07/02, 13:00（美東）報價延遲15分鐘
555.14K總市值
虧損本益比TTM
關鍵數據
1.350今開
1.460最高
208.73K成交量
虧損本益比TTM
虧損本益比動
--股利TTM
52.64%換手率
1.360昨收
1.320最低
201.75K成交額
虧損本益比靜
-0.02市淨率
0.00%股息率 TTM
-281.72%ROA
18.80052週最高
1.76量比
-26.97M淨利潤
396.53K總股本
-4.2173每股盈餘TTM
1.06Beta
-5396.85%ROE
1.90652週最低
10.29%振幅
100.00%毛利率
555.14K總市值
-6.00回報/風險
5.33%風險率
TradingKey VolitionRX Ltd股票評分
單位: USD 更新時間: 2026-07-02操作建議
VolitionRX Ltd當前公司基本面數據相對穩定，增長潛力很大。當前估值合理，在生物技術與醫療研究行業排名139/387位。機構持股佔比非常高，近一月多位分析師給出公司評級為買入。最高目標價為16.97。中期看，股價處於下降通道。近一個月，市場表現非常差，但公司基本面和技術面得分較高。目前股價在壓力位和支撐位之間，可以做區間波段操作。
VolitionRX Ltd評分
壓力支撐
由於公司未披露，未能獲取相關數據
多維評測
本期評分
上期評分
公司輿情
過去24小時
熱度
過冷
過熱
看好
VolitionRX Ltd亮點
亮點風險
VolitionRx Limited is a multi-national company focused on advancing the science of epigenetics. The Company is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, it is developing and commercializing blood tests to help diagnose and monitor a range of diseases, including cancers and diseases associated with NETosis, such as sepsis. Its key pillars are Nu.Q Vet, Nu.Q NETs, Nu.Q Discover, Nu.Q Cancer, and Capture-PCR. The Nu.Q Vet Cancer Test is commercially available as a cancer screening test in dogs. Nu.Q NETs is monitoring the immune system to save lives. Nu.Q Discover is a complete solution to profiling nucleosomes. Nu.Q Cancer monitoring disease progression, response to treatment and minimal residual disease. Capture-PCRTM is isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection.
業績高增長
公司營業收入穩步增長，連續3年增長122.80%
業績增長期
公司處於發展階段，最新年度總收入1.73M美元
估值高估
公司最新PE估值-0.33，處於3年歷史高位
機構減倉
最新機構持股1.13M股，環比減少15.69%
活躍度降低
近期活躍度降低，過去20天平均換手率-0.83
分析師目標
基於
5
分析師
買入
評級
16.966
目標均價
+1147.50%
漲幅空間
VolitionRX Ltd新聞
即將為您帶來更多新聞，敬請期待。 。 。
財務指標
每股收益
由於公司未披露，未能獲取相關數據
營業總收入
由於公司未披露，未能獲取相關數據
VolitionRX Ltd簡介
VolitionRx Limited is a multi-national company focused on advancing the science of epigenetics. The Company is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, it is developing and commercializing blood tests to help diagnose and monitor a range of diseases, including cancers and diseases associated with NETosis, such as sepsis. Its key pillars are Nu.Q Vet, Nu.Q NETs, Nu.Q Discover, Nu.Q Cancer, and Capture-PCR. The Nu.Q Vet Cancer Test is commercially available as a cancer screening test in dogs. Nu.Q NETs is monitoring the immune system to save lives. Nu.Q Discover is a complete solution to profiling nucleosomes. Nu.Q Cancer monitoring disease progression, response to treatment and minimal residual disease. Capture-PCRTM is isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection.
公司代碼VNRX
公司VolitionRX Ltd
CEOButera (Salvatore Thomas)
網址https://volition.com/
相關品種
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%熱門品種
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
常見問題
VolitionRX Ltd(VNRX)的當前股價是多少？
VolitionRX Ltd(VNRX)的當前股價是 1.40。
VolitionRX Ltd 的股票代碼是什麼？
VolitionRX Ltd的股票代碼是VNRX。
VolitionRX Ltd股票的52週最高點是多少？
VolitionRX Ltd股票的52週最高點是18.80。
VolitionRX Ltd股票的52週最低點是多少？
VolitionRX Ltd股票的52週最低點是1.91。
VolitionRX Ltd的市值是多少？
VolitionRX Ltd的市值是153.47M。
現在VolitionRX Ltd(VNRX)的股票是買入、持有還是賣出？
根據分析師評級，VolitionRX Ltd(VNRX)的總體評級為買入，目標價格為16.97。
VolitionRX Ltd(VNRX)股票的每股收益（EPS TTM）是多少
VolitionRX Ltd(VNRX)股票的每股收益（EPS TTM）是-4.37。